Fair Value Calculator Fair Value Calculator
EN DE

Symbiox Investment & Trading Co (539278) Fair Value & Analysis

Other · IN · Market cap ₹25.7M

SI Symbiox Investment & Trading Co 539278 · BSE
Price₹1.55
Fair Value₹1.56
Upside+0.6%
Quality52/100
Watch Symbiox Investment & Trading Co for free — get notified when fair value or trend changes. Watch for free
Evidence: High Range ₹1.14 – ₹1.96

Fair value as of: Jul 5, 2026

From 20 valuation models · updated today

Share price −6.1% over the past month.

Price vs Fair Value (12 months)

₹3.59 ₹1.46 Fair Value ₹1.56 Jul 2025 Jul 2026

12‑month range ₹1.46 – ₹3.59 · fair‑value band ₹1.14 – ₹1.96 · the ₹1.55 price screens below the ₹1.56 fair value. As of Jul 5, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

Symbiox Investment & Trading Co (539278) currently trades at ₹1.55, while our model-based Fair Value estimate is ₹1.56 — implying the stock looks roughly 0.6% undervalued today. We read business quality at 52/100 (solid quality), in the Other sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Net debt stands at ₹2.5M. The stock trades on a trailing P/E of 124.2. Fundamentals as of Jul 5, 2026

Key figures & financial health

Free cash flow ₹27.3M FY2026
P/E ratio 124.2
EPS (TTM) ₹0.0066
Net debt ₹2.5M FY2020

Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.

About the company

Symbiox Investment & Trading Co Ltd trades in sarees in India. It offers sarees with embroidery work of stones, beads, etc., including plain, designer, cotton, and silk sarees. The company is also involved in financing activities. Symbiox Investment & Trading Co Ltd was incorporated in 1979 and is based in Kolkata, India.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

Symbiox Investment & Trading Co reported revenue of ₹16.0M in FY2026 versus ₹10.5M in FY2022, a compound +11.1%/yr. Reported net income was ₹1.5M in FY2026, compounding +2.3%/yr from FY2022.

Revenue +11.1%/yr
FY22 ₹10.5M
FY23 ₹39.8M
FY24 ₹39.0M
FY25 ₹27.6M
FY26 ₹16.0M
Net income +2.3%/yr
FY22 ₹1.4M
FY23 ₹1.6M
FY24 ₹2.1M
FY25 ₹1.9M
FY26 ₹1.5M

Is 539278 fairly valued? → Check now

Similar stocks

6 more Other stocks, each showing price versus our Fair Value estimate (as of Jul 5, 2026).

Stock Price Fair Value vs Fair Value
There MOH €521.90 €269.92 -48%
Sony Corporation SON1 €17.58 €39.38 +124%
Federal Home Loan Mortgage Corporation FREJO $16.84 $64.93 +286%
533278 533278 ₹438.60 ₹720.31 +64%
Nestl?? India Limited 500790 ₹1,459 ₹279.60 -81%
540376 540376 ₹3,993 ₹1,806 -55%

Explore undervalued stocks

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is Symbiox Investment & Trading Co (539278) undervalued?
As of Jul 5, 2026, our model estimates a fair value of ₹1.56 versus a price of ₹1.55 — about +1% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 539278?
Our model-based fair value for Symbiox Investment & Trading Co is ₹1.56 (as of Jul 5, 2026), built from audited fundamentals. The current price is ₹1.55.
What is the quality score of 539278?
Symbiox Investment & Trading Co has a Quality Score of 52/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the net profit margin of 539278?
The net profit margin of Symbiox Investment & Trading Co is about 0.0%, meaning it keeps roughly 0.0% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.